8-K: Baxter Exceeds Earnings Expectations in Q3 2024, Navigates Hurricane Impact and Kidney Care Sale

Baxter International Inc. reported strong third-quarter 2024 results, exceeding earnings guidance, while also managing the impact of Hurricane Helene and progressing with the sale of its Kidney Care business.

Summary

• Baxter's third-quarter 2024 sales reached $3.85 billion, including $2.70 billion from continuing operations.
• The company's adjusted diluted earnings per share (EPS) were $0.80, surpassing the previously issued guidance of $0.77 to $0.79.
• Sales from continuing operations increased by 4% on both a reported and constant currency basis, with growth across all segments.
• The Kidney Care business is now reported as a discontinued operation, with sales increasing mid-single digits.
• Hurricane Helene caused a temporary production shutdown at the North Cove facility, but the highest-throughput IV solutions line has been restarted.
• Baxter expects a negative impact of approximately $200 million on total company fourth-quarter sales due to the hurricane, with a $0.15 to $0.20 per share negative impact on adjusted diluted EPS.
• The sale of the Kidney Care segment to Carlyle is expected to close in late 2024 or early 2025, with net after-tax proceeds estimated to be between $3.15 and $3.25 billion.
• Following the Kidney Care divestiture, Baxter is targeting operational sales growth of 4% to 5% annually and a full-year 2025 adjusted operating margin of approximately 16.5%.

Sentiment

Score: 7

Explanation: The sentiment is positive due to exceeding earnings expectations and progress on the Kidney Care sale, but tempered by the negative impact of Hurricane Helene and the challenges of the divestiture.

Positives

• Baxter exceeded its third-quarter earnings guidance, demonstrating strong financial performance.
• The company achieved growth across all segments of its continuing operations.
• The restart of the highest-throughput IV solutions line at the North Cove facility is ahead of original expectations.
• The Kidney Care sale is expected to generate higher net after-tax proceeds than initially anticipated.
• Baxter is targeting solid operational sales growth and margin expansion following the Kidney Care divestiture.

Negatives

• Hurricane Helene caused significant disruption to the North Cove manufacturing facility, impacting production and sales.
• The company expects a negative impact of approximately $200 million on fourth-quarter sales due to the hurricane.
• The Injectables & Anesthesia division experienced a high single-digit decline in sales due to order timing and supply constraints.
• The Healthcare Systems & Technologies segment saw declines internationally and in the U.S. Front Line Care division.

Risks

• The full restoration of the North Cove facility to pre-hurricane levels is still uncertain.
• The company faces challenges in mitigating stranded costs and loss of transition service agreement (TSA) income following the Kidney Care divestiture.
• There are risks associated with the timing and completion of the Kidney Care sale, including regulatory approvals and closing conditions.
• The company's financial outlook is subject to the impact of global economic conditions, regulatory changes, and competitive pressures.

Future Outlook

Baxter expects a negative impact on fourth-quarter 2024 results due to Hurricane Helene, but reaffirms its preliminary financial expectations following the Kidney Care divestiture, targeting 4% to 5% annual operational sales growth and a 16.5% adjusted operating margin in 2025.

Management Comments

• Jos (Joe) E. Almeida, chair, president and chief executive officer, stated that Baxter delivered positive performance in the third quarter of 2024 and continues to execute against its strategic transformation.
• Almeida recognized the tireless efforts of the North Cove team and other Baxter colleagues in site restoration and addressing supply continuity.
• Almeida also expressed gratitude to ASPR, FDA, the State of North Carolina and HHS for their support.

Industry Context

This announcement reflects a trend in the medical technology industry where companies are streamlining their portfolios to focus on core businesses. The divestiture of the Kidney Care business allows Baxter to concentrate on its Medical Products & Therapies, Healthcare Systems & Technologies, and Pharmaceuticals segments. The impact of Hurricane Helene highlights the vulnerability of supply chains in the healthcare sector and the importance of disaster recovery planning.

Comparison to Industry Standards

• Baxter's 4% sales growth in continuing operations is comparable to other large medical device companies, such as Medtronic and Abbott, which have also reported mid-single-digit growth in recent quarters.
• The adjusted EPS of $0.80 is a positive result, exceeding the company's own guidance and indicating effective cost management and operational efficiency.
• The divestiture of the Kidney Care business is similar to moves by other healthcare companies to focus on higher-growth areas, such as Johnson & Johnson's spin-off of its consumer health business.
• The impact of Hurricane Helene on Baxter's operations is a reminder of the supply chain risks faced by the industry, similar to the disruptions experienced by other companies due to natural disasters or geopolitical events.
• Baxter's target of 4-5% operational sales growth post-divestiture is in line with the growth expectations for the medical technology sector, which is driven by factors such as an aging population and technological advancements.

Stakeholder Impact

• Shareholders will be impacted by the positive earnings results and the strategic divestiture of the Kidney Care business.
• Employees at the North Cove facility have been affected by the hurricane, but the company is working to restore operations and support them.
• Customers may experience some supply disruptions due to the hurricane, but the company is working to minimize the impact.
• Suppliers may be affected by the production disruptions at the North Cove facility.
• Creditors will be impacted by the company's financial performance and the proceeds from the Kidney Care sale.

Next Steps

• Baxter will continue to work on restoring full production at the North Cove facility.
• The company will proceed with the sale of the Kidney Care business, expected to close in late 2024 or early 2025.
• Baxter will focus on mitigating stranded costs and loss of TSA income following the divestiture.
• The company will provide further updates on the North Cove restoration efforts on its website.
• Baxter will continue to execute its strategic transformation and cost-containment initiatives.

Key Dates

Keywords

Baxter, earnings, Kidney Care, Hurricane Helene, divestiture, sales, EPS, North Cove, manufacturing, medical devices, Carlyle, Vantive